Evidence map›Paper›PMID 39829337›Full record

ArticleDiabetes, obesity & metabolism2025

Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.

Sophie Lamothe, Ines Belalem, Marie-Christine Vantyghem, Estelle Nobecourt, Héléna Mosbah, Sophie Béliard, Brigitte Delemer, Hippolyte Dupuis, Paul Vandenbroere, Nicolas Scheyer and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.The Journal of clinical endocrinology and metabolism · 2026
    Observational
  2. Hematopoietic stem cell transplantation-associated partial lipodystrophy.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sophie LamotheEndocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.ORCID 0009-0000-6853-7742
Ines BelalemEndocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Marie-Christine VantyghemDepartment of Endocrinology, Diabetology and Metabolism, Lille University Hospital, University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.
Estelle NobecourtDepartment of Endocrinology, Diabetology and Metabolism, La Réunion University Hospital, Saint Pierre de la Réunion, France.
Héléna MosbahDepartment of Endocrinology, Diabetology and Nutrition CHU La Milétrie, Poitiers, France.
Sophie BéliardDepartment of Nutrition, Metabolic Diseases, Endocrinology, Aix Marseille University, Inserm, INRA, C2VN, La Conception Hospital, Marseille, France.
Brigitte DelemerDepartment of Endocrinology, Diabetes and Nutrition, Reims University Hospital, Hospital Robert-Debré, Reims, France.
Hippolyte DupuisDepartment of Endocrinology, Diabetology and Metabolism, Lille University Hospital, University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.
Paul VandenbroereDepartment of Endocrinology, Diabetology and Metabolism, Lille University Hospital, University of Lille, INSERM U1190, European Genomic Institute for Diabetes, Lille, France.
Nicolas ScheyerDepartment of Endocrinology, Diabetology and Nutrition, Nancy University Hospital, Nancy, France.
Chloé AmouyalDepartment of Diabetology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University, Nutrition and Obesities: Systemic Approaches, NutriOmics, Research Unit, Sorbonne Université, Paris, France.
Samy HadjadjL'institut du thorax, Nantes University, CHU Nantes, CNRS, INSERM, Nantes, France.
Sonja JanmaatEndocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.
Corinne VigourouxEndocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.ORCID 0000-0002-8181-4721
Camille VatierEndocrinology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris, France.

Funding

Assistance Publique-Hôpitaux de ParisCorinne Vigouroux represents PRISIS in the European Reference Network on Rare Endocrine Conditions - Project ID No 739527French Ministry of Solidarity and HealthSorbonne University, France
6 · The paper itself

Abstract

aimTo describe the effects of Glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with familial partial lipodystrophy (FPLD) assessed in a real-life setting in a national reference network. PATIENTS AND

methodsWe retrospectively collected clinical and metabolic parameters in patients with FPLD in the French lipodystrophy reference network, who initiated GLP-1RA. Data were recorded before, at one-year (12 ± 6 months) and at the latest follow-up on GLP-1RA therapy (≥18 months).

resultsSeventy-six patients (89.4% of women), diagnosed with LMNA-related FPLD2 (n = 57), PPARG-related FPLD3 (n = 4), PLIN1-related FPLD4 (n = 5) or FPLD1 (n = 10) initiated GLP-1RA therapy between 2008 and 2024. Patients were aged a median (IQR) 48 years (34.5-57), body mass index (BMI) was 26.0 kg/m

conclusionGLP-1RA significantly improved BMI, HbA1c and triglycerides in a large majority of patients with FPLD. Larger and prospective controlled studies are warranted for identification of predictive factors and safety.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLipodystrophy, Familial PartialAdultBody Mass IndexFemaleFranceGlycated HemoglobinHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic Agentsdyslipidaemiafatty liver diseaseGLP‐1 analogueglycaemic controlinsulin resistancereal‐world evidence

Identifiers

PMID39829337
PMCPMC11885082

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.